

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: RICCARDI, Carlo

Application No.: 09/403,861

Filed: February 11, 2000

For: INTRACELLULAR MODULATORS OF APOPTOPIC CELL DEATH PATHWAYS

Art Unit: 1635

Examiner: J. Epps

Washington, D.C.

Atty.'s Docket: RICCARDI=1

Date: August 14, 2002

BY HANDCARRY

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [XX] Amendment After Final Rejection []
in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 8	MINUS	** 20	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
Response Filed Within
[] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00
Month After Time Period Set

Other Than Small Entity
Response Filed Within
[] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00
Month After Time Period Set

[] Less fees (\$) already paid for ___ month(s) extension of time on _____.

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____.


[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$_____.

[] A check in the amount of \$_____ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
Allen C. Yun
Registration No. 37,971

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

RECEIVED
TECH CENTER 1600/2900
02 AUG 14 PM 3:02
AUG 19 2002
TECH CENTER 1600/2900

RECEIVED
AUG 19 2002
TECH CENTER 1600/2000

AFTER FINAL PROCEDURE - PLEASE EXPEDITE HANDLING

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

21/F
RF/NE
EWilliam
8-22-02

In re Application of:)	Art Unit: 1635
)	
RICCARDI, Carlo)	Examiner: J. Epps
)	
Appln. No.: 09/403,861)	Washington, D.C.
)	
Filed: February 11, 2000)	August 14, 2002
)	
For: INTRACELLULAR MODULATORS)	Atty. Docket: RICCARDI=1
OF APOPTOTIC CELL DEATH)	
PATHWAYS)	BY HANDCARRY
)	
Confirmation No. 7791)	

AMENDMENT AFTER FINAL REJECTION

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of May 21, 2002,
please amend as follows:

IN THE CLAIMS

Please replace claims 41, 43, 44, 47, and 48 with
new amended claims 41, 43, 44, 47, and 48 as follows below. A
marked up version of the amended claims to show the changes
made is attached hereto.

41(Amended). A GILR protein encoded by the
nucleotide sequence of SEQ ID NO:1 or by a nucleotide sequence

21/F
SUB
G1